Literature DB >> 15363544

An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer.

Chung-Wei Fan1, Hong-Arh Fan, Soon-Hwei Hsu, Chang-Chuan Chan, Shih-Yuan Chen, Yuan-Hsun Hsu, Err-Cheng Chan.   

Abstract

The goal of this study was to develop a simple and rapid in vitro drug resistance assay to ascertain the effectiveness of 5-fluorouracil (5-FU) for the individual therapy of colorectal cancer. Colorectal cancer cells were isolated from tumor specimens and, after 4h exposure to high doses of 5-FU cell viability was measured with an ATP assay. The average IC50 concentration for 5-FU was calculated as 4000 microg/ml from 35 patients' tumors. The tumor cells were defined as extreme drug resistance with a survival rate 1 standard deviation (SD) over IC50, low drug resistance (LDR) with a survival rate 1 SD below IC50, and intermediate drug resistance (IDR) with survival rate between these two. The drug resistant assay for 102 patients' cancer cells showed that the proportion of patients with LDR to 5-fluorouracil was 19%. The in vitro drug resistance of the cancer cells was not correlated with cancer stages or by patient sex or age. However, most mucinous and poor differentiated cancer cells showed extreme or IDR. The in vitro ATP assay values for 25 Duke's D patients receiving postoperative 5-FU chemotherapy were comparable with clinical postchemotherapy responses. The sensitivity and specificity of the assay were 100 and 95%, respectively. This short time-high dose drug exposure assay may serve as an aid to improve 5-FU treatment for individual chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363544     DOI: 10.1016/j.canlet.2004.06.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

Review 1.  Recent applications of chemosensitivity tests for colorectal cancer treatment.

Authors:  Yong Sik Yoon; Jin Cheon Kim
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

2.  In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.

Authors:  Hee Seung Kim; Tae Joong Kim; Hyun Hoon Chung; Jae Weon Kim; Byung Gie Kim; Noh Hyun Park; Yong Sang Song; Duk Soo Bae; Soon Beom Kang
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-16       Impact factor: 4.553

3.  Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.

Authors:  Giuseppe S Sica; Cristina Fiorani; Carmine Stolfi; Giovanni Monteleone; Eleonora Candi; Ivano Amelio; Valeria Catani; Simone Sibio; Andrea Divizia; Giorgia Tema; Edoardo Iaculli; Achille L Gaspari
Journal:  Oncotarget       Date:  2015-05-30

Review 4.  Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.

Authors:  Shyam S Mohapatra; Surinder K Batra; Srinivas Bharadwaj; Michael Bouvet; Bard Cosman; Ajay Goel; Wilma Jogunoori; Michael J Kelley; Lopa Mishra; Bibhuti Mishra; Subhra Mohapatra; Bhaumik Patel; Joseph R Pisegna; Jean-Pierre Raufman; Shuyun Rao; Hemant Roy; Maren Scheuner; Satish Singh; Gitanjali Vidyarthi; Jon White
Journal:  Dig Dis Sci       Date:  2018-03-23       Impact factor: 3.199

5.  Deciphering cellular states of innate tumor drug responses.

Authors:  Esther Graudens; Virginie Boulanger; Cindy Mollard; Régine Mariage-Samson; Xavier Barlet; Guilaine Grémy; Christine Couillault; Malika Lajémi; Dominique Piatier-Tonneau; Patrick Zaborski; Eric Eveno; Charles Auffray; Sandrine Imbeaud
Journal:  Genome Biol       Date:  2006-03-15       Impact factor: 13.583

6.  Anti-EGFR-Coated Gold Nanoparticles In Vitro Carry 5-Fluorouracil to Colorectal Cancer Cells.

Authors:  Raquel B Liszbinski; Graziela G Romagnoli; Carolina M Gorgulho; Caroline R Basso; Valber A Pedrosa; Ramon Kaneno
Journal:  Materials (Basel)       Date:  2020-01-14       Impact factor: 3.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.